Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial

  1. Delforge, M.
  2. Otero, P.R.
  3. Shah, N.
  4. Moshkovich, O.
  5. Braverman, J.
  6. Dhanda, D.S.
  7. Lanar, S.
  8. Devlen, J.
  9. Miera, M.
  10. Gerould, H.
  11. Campbell, T.B.
  12. Munshi, N.C.
Zeitschrift:
Leukemia Research

ISSN: 1873-5835,  0145-2126

Datum der Publikation: 2023

Ausgabe: 129

Art: Artikel

DOI: 10.1016/J.LEUKRES.2023.107074 GOOGLE SCHOLAR lock_openOpen Access editor
Datenquelle: Scopus